VYNE Therapeutics (NASDAQ:VYNE) Sees Large Volume Increase – Time to Buy?

VYNE Therapeutics Inc. (NASDAQ:VYNE) saw unusually-strong trading volume on Monday . 15,572 shares changed hands during mid-day trading, an increase of 55% from the previous session’s volume of 10,032 shares.The stock last traded at $25.20 and had previously closed at $25.45.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of VYNE Therapeutics in a research note on Monday, May 4th. Three equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce”.

VYNE Therapeutics Stock Performance

The business’s 50-day moving average price is $33.93 and its 200 day moving average price is $31.50. The stock has a market capitalization of $18.98 million, a PE ratio of -74.54 and a beta of 2.00.

VYNE Therapeutics (NASDAQ:VYNE) last issued its quarterly earnings data on Friday, May 15th. The company reported ($4.00) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($9.00) by $5.00. The company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.20 million. VYNE Therapeutics had a negative return on equity of 70.42% and a negative net margin of 4,726.21%.

VYNE Therapeutics Announces Dividend

The firm also recently announced a special dividend, which was paid on Thursday, July 23rd. Shareholders of record on Wednesday, July 22nd were paid a $19.00 dividend.

Institutional Trading of VYNE Therapeutics

Large investors have recently modified their holdings of the business. T3 Companies LLC purchased a new position in shares of VYNE Therapeutics during the fourth quarter worth about $548,000. Anson Funds Management LP purchased a new stake in VYNE Therapeutics in the fourth quarter valued at approximately $739,000. Nantahala Capital Management LLC purchased a new stake in VYNE Therapeutics in the fourth quarter valued at approximately $580,000. KVP Capital Advisors LP purchased a new stake in VYNE Therapeutics in the fourth quarter valued at approximately $290,000. Finally, Jane Street Group LLC bought a new stake in VYNE Therapeutics during the second quarter valued at approximately $206,000. Institutional investors own 83.78% of the company’s stock.

About VYNE Therapeutics

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.